Overview
Domain 4 asks what happens after the plan starts. Content centers on evaluating the effectiveness of the plan of care and on modifying and monitoring the ongoing plan. In practice that means knowing when to recheck, what to measure and what to do with the result: rechecking A1C about three months after a change in diabetes therapy, checking TSH after a levothyroxine adjustment, checking potassium and creatinine after starting an ACE inhibitor, and reassessing depression symptoms after an adequate antidepressant trial.
At 15% of scored items, about 20 questions, this is the smallest domain, and it dropped from 30 items on the 2023 blueprint. The FNP handbook printed in 06/2026 repeats the Plan task list under Evaluate, apparently in error, so this page organizes the domain into two documented subtopics. Evaluation items still decide marks, because they test whether you escalate, continue or stop therapy at the right time.
How it's tested
Evaluate items describe a patient returning after treatment began, often with a new lab value, symptom report or adverse effect, and ask for the best next step. Options usually include continuing, intensifying, switching, stopping or referring, and the correct answer depends on timing and the size of the change.
-
Goal not met
A follow-up result shows the target was not reached and you choose the next guideline-based adjustment.
-
Monitoring interval
A therapy was started or changed and you choose when and what to recheck.
-
Adverse effect or failure
A side effect or lack of improvement is reported and you decide whether to continue, switch or stop.
Two weeks after starting lisinopril, a patient's creatinine rose from 1.0 to 1.2 mg/dL and potassium is normal. Stopping the drug is tempting, but a rise of up to about 30% is expected as glomerular pressure falls and usually stabilizes. The right step is to continue and recheck. A larger rise or significant hyperkalemia would change that decision.
Tasks 2
Official tasks from the AANPCB outline, in outline order.
4.1 Evaluate the effectiveness of the plan of careJudging response to treatment against goals and expected timelines.
- What it means
- This subtopic covers measuring whether treatment is achieving its goals: comparing blood pressure, A1C, lipid, symptom and functional outcomes against targets, reassessing acute illness that fails to improve in the expected time, and checking adherence, technique and patient-reported outcomes before concluding a therapy has failed.
- What to understand
- Effectiveness is judged at the right time with the right measure. A1C reflects about three months of glucose control, so earlier rechecks mislead. An antidepressant needs several weeks at an adequate dose before response can be judged. Children with acute otitis media who do not improve within 48 to 72 hours need reassessment. Before calling a treatment a failure, confirm adherence, inhaler technique, lifestyle factors and correct diagnosis. Patient goals and quality of life count as outcomes alongside lab numbers.
- How it shows up
- A follow-up visit is described and you judge whether the plan is working, or what must be checked before changing it.
- Common confusion
- Escalating therapy without first confirming adherence, correct technique or an adequate trial period.
4.2 Modify and monitor ongoing plan of careAdjusting, intensifying or deprescribing therapy and setting monitoring.
- What it means
- This subtopic covers changing the plan based on outcomes: intensifying therapy when goals are unmet, switching after adverse effects, deprescribing in older adults, setting monitoring for drugs with known risks, and coordinating transitions of care such as hospital discharge with medication reconciliation and timely follow-up.
- What to understand
- Know common monitoring rules: TSH about six to eight weeks after a levothyroxine change, potassium and creatinine soon after starting an ACE inhibitor or ARB, INR for warfarin, and periodic vitamin B12 with long-term metformin. In type 2 diabetes with ASCVD, heart failure or CKD, add an agent with proven organ benefit. Deprescribing removes drugs whose risks now outweigh benefits, particularly in frail older adults. After discharge, reconcile medications and arrange prompt follow-up.
- How it shows up
- A result or adverse effect is given and you choose the modification and monitoring plan that fits current guidance.
- Common confusion
- Stopping a useful drug for an expected, acceptable change, or keeping a drug whose risk now exceeds its benefit.
High-yield concepts
The terms, rules and formulas this domain turns into questions most often.
-
A1C recheck timing
Recheck about every three months when therapy changes or goals are unmet, and at least twice yearly when stable.
- Remember
- A1C reflects roughly three months of glycemia.
- Tested as
- Diabetes follow-up items.
- Trap
- Rechecking after two weeks.
-
Levothyroxine monitoring
Recheck TSH about six to eight weeks after starting or changing the dose.
- Remember
- TSH needs weeks to reach a new steady state.
- Tested as
- Thyroid follow-up items.
- Trap
- Adjusting the dose after one week.
-
ACE inhibitor creatinine rise
A creatinine rise up to about 30% after starting is generally acceptable.
- Remember
- Recheck potassium and creatinine early.
- Tested as
- Renal monitoring items.
- Trap
- Stopping the drug for a small rise.
-
Adequate antidepressant trial
Response is judged after several weeks at an adequate dose.
- Remember
- Reassess with a validated tool such as the PHQ-9.
- Tested as
- Depression follow-up items.
- Trap
- Switching after one week.
-
Treatment failure in otitis media
No improvement after 48 to 72 hours of amoxicillin warrants reassessment and a change in therapy.
- Remember
- Confirm the diagnosis first.
- Tested as
- Pediatric infection follow-up items.
- Trap
- Continuing the same drug indefinitely.
-
Diabetes intensification with ASCVD
Add a GLP-1 receptor agonist or SGLT2 inhibitor with proven cardiovascular benefit.
- Remember
- Comorbidity guides the choice.
- Tested as
- Diabetes escalation items.
- Trap
- Defaulting to a sulfonylurea.
-
Statin follow-up
Check a lipid panel 4 to 12 weeks after starting to assess response and adherence.
- Remember
- Assess muscle symptoms clinically.
- Tested as
- Lipid follow-up items.
- Trap
- Routine CK monitoring without symptoms.
-
Metformin long-term monitoring
Monitor renal function and periodically check vitamin B12.
- Remember
- Metformin is contraindicated when eGFR is below 30.
- Tested as
- Chronic therapy monitoring items.
- Trap
- Forgetting B12 deficiency.
-
Deprescribing
Reducing or stopping medicines whose harms outweigh benefits.
- Remember
- Especially relevant in frail older adults.
- Tested as
- Older adult follow-up items.
- Trap
- Adding drugs without reviewing the list.
-
Transitions of care
Medication reconciliation and timely follow-up after discharge or between settings.
- Remember
- Discrepancies cause preventable harm.
- Tested as
- Care coordination items.
- Trap
- Assuming the discharge list is correct.
-
Adherence check first
Confirm the patient takes the drug correctly before escalating.
- Remember
- Inhaler technique counts.
- Tested as
- Uncontrolled disease items.
- Trap
- Adding a second drug immediately.
Side by side
Concepts candidates mix up, compared on the point that decides the answer.
Continue, intensify, switch or stop
| Concept | Meaning | Key difference | Common trap |
|---|---|---|---|
| Continue | Goal met or trial not yet long enough | No change, keep monitoring | Changing too early |
| Intensify | Goal not met despite adherence | Add or increase therapy | Escalating before checking adherence |
| Switch | Intolerable or serious adverse effect | Different agent or class | Switching within a class after angioedema |
| Stop or deprescribe | Harm outweighs benefit | Remove the drug safely | Keeping a drug out of habit |
Common monitoring intervals
| Concept | Meaning | Key difference | Common trap |
|---|---|---|---|
| A1C | About three months after a change | Reflects average glycemia | Rechecking in weeks |
| TSH on levothyroxine | About six to eight weeks after a dose change | Allows steady state | Adjusting too quickly |
| Potassium and creatinine on ACE inhibitor | Soon after starting or dose increase | Detects hyperkalemia and renal change | Skipping the early check |
Exam traps
Each trap is an answer that looks right. Learn the clue that should change your mind.
-
Recheck A1C in two weeks
- What candidates pick
- Order a repeat A1C two weeks after starting metformin.
- Why it looks right
- It seems proactive.
- Why it's wrong
- A1C reflects about three months of glycemia, so an early value cannot show the effect of the change.
Clue to watch for A recent therapy change and a question about follow-up timing.
-
Stop lisinopril
- What candidates pick
- Stop an ACE inhibitor because creatinine rose 15%.
- Why it looks right
- Any creatinine rise looks harmful.
- Why it's wrong
- A rise up to about 30% is generally acceptable and expected; continue with monitoring unless potassium or creatinine rise further.
Clue to watch for A modest creatinine increase with normal potassium.
-
Add a second drug immediately
- What candidates pick
- Add another controller for uncontrolled asthma at the first follow-up.
- Why it looks right
- Symptoms are not controlled.
- Why it's wrong
- Inhaler technique, adherence and triggers should be checked before stepping up therapy.
Clue to watch for A patient with poor control and no mention of technique review.
-
Antidepressant failure at one week
- What candidates pick
- Switch an SSRI after one week because mood has not improved.
- Why it looks right
- The patient still feels depressed.
- Why it's wrong
- Full response usually takes several weeks at an adequate dose, so early switching is premature.
Clue to watch for A short interval since starting the drug.
-
Sulfonylurea for every escalation
- What candidates pick
- Add a sulfonylurea for a patient with diabetes and established ASCVD.
- Why it looks right
- It lowers A1C cheaply.
- Why it's wrong
- With ASCVD, guidelines favor a GLP-1 receptor agonist or SGLT2 inhibitor with proven cardiovascular benefit.
Clue to watch for A comorbidity such as ASCVD, heart failure or CKD in the stem.
-
Discharge list is correct
- What candidates pick
- Continue the discharge medication list without review.
- Why it looks right
- The hospital prepared it.
- Why it's wrong
- Medication reconciliation at transitions catches omissions, duplications and interactions that commonly occur.
Clue to watch for A first visit after hospital discharge.
Answer framework
Work through these steps for any Domain 4 follow-up or monitoring vignette.
- Identify the goal of the original plan and the outcome measure, such as blood pressure, A1C, TSH, PHQ-9 score or symptom resolution.
- Check that enough time has passed for the measure to reflect the change before judging the result, for example about three months for A1C.
- Before escalating, confirm adherence, technique, lifestyle factors and that the original diagnosis is still correct, since an apparent failure may be a missed diagnosis.
- Choose to continue, intensify, switch or stop, using comorbidities and adverse effects to guide the specific change, such as an agent with cardiovascular benefit.
- Set the next monitoring interval and coordinate care, including medication reconciliation at any transition and clear instructions on when to return.
Practice question
Want more like this? The AANPCB FNP practice test has questions for every domain.
Checklist
0 of 10
Tick each one you can do without notes. Your ticks stay in this browser.
Study strategy
Evaluate is the smallest domain, so study it efficiently by linking it to the conditions you already reviewed for Plan. For each chronic condition in your Plan table, add two columns: what to monitor and when, and what to do if the goal is not met. This doubles the value of your Plan study and covers most Evaluate items.
Next, memorize a short list of monitoring rules: A1C timing, TSH after levothyroxine changes, potassium and creatinine with ACE inhibitors and ARBs, INR with warfarin, lipid panels after statins, and long-term metformin checks. Learn the acceptable creatinine rise after starting an ACE inhibitor, because it is a frequent trap.
Then practice follow-up vignettes. In each, ask whether enough time has passed, whether adherence was confirmed, and whether a comorbidity points to a specific next drug. Finally, review deprescribing and transitions of care for older adults, since older adults carry 30% of scored items. Keep this domain to about a tenth of your total study time, but do not skip it, as its 20 items can still decide a close result.
FAQ
How much of the AANPCB FNP exam is the Evaluate domain?
Evaluate is 15% of scored content, 20 of 135 scored items, making it the smallest of the four practice domains.
Did the Evaluate domain shrink?
Yes. The 2024 blueprint cut Evaluate from 30 to 20 scored items, while Assess grew from 36 to 43.
What tasks belong to Evaluate?
The 06/2026 FNP handbook repeats the Plan tasks under Evaluate, likely in error. This guide uses two subtopics: evaluating plan effectiveness, and modifying and monitoring the ongoing plan.
How soon should A1C be rechecked after a change?
About three months, since A1C reflects average glucose over roughly that period. Stable patients at goal are checked at least twice a year.
Is a creatinine rise after starting an ACE inhibitor a reason to stop?
Not usually. A rise up to about 30% is generally acceptable; larger rises or hyperkalemia need reassessment.
Are transitions of care tested?
Yes. Transitions of care is listed among the applied knowledge areas, so expect items on discharge follow-up and medication reconciliation.
Test your Domain 4 knowledge
You have reviewed outcome evaluation, monitoring intervals, therapy intensification and transitions of care. Check whether you can choose the right follow-up decision under exam timing.
Keep going
- Training Training Built on your Weak areas
- Practice test Questions by domain, with explanations
- Mock exam Full length, timed like the real exam
- Readiness test Find your weakest domain in minutes
- Cheat sheet Key terms and formulas on one page
- Ask the AANPCB FNP AI tutor Get any concept explained your way